Therriault, J;
              
      
            
                Benedet, A;
              
      
            
                Pascoal, TA;
              
      
            
                Savard, M;
              
      
            
                Ashton, N;
              
      
            
                Chamoun, M;
              
      
            
                Tissot, C;
              
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
            ... Rosa-Neto, P; + view all
            
          
      
        
        
        
    
  
(2020)
  Determining Amyloid-β positivity using [18F]AZD4694 PET imaging.
The Journal of Nuclear Medicine
      
    
    
    
         10.2967/jnumed.120.245209.
   (In press).
  
      
    
  
Preview  | 
            
              
Text
 J Nucl Med-2020-Therriault-jnumed.120.245209.pdf - Accepted Version Download (5MB) | Preview  | 
          
Abstract
Amyloid-β deposition into plaques is a pathological hallmark of Alzheimer’s disease (AD) appearing years before the onset of symptoms. Although cerebral amyloid-β deposition occurs on a continuum, dichotomization into positive and negative groups has advantages for diagnosis, clinical management and population enrichment for clinical trials. 18F-AZD4694 (also known as 18F-NAV4694) is an amyloid-β imaging ligand with high affinity for amyloid-β plaques. Despite being employed in multiple academic centers, no studies have assessed a quantitative cut-off for amyloid-β positivity using 18F-AZD4694 PET. Methods: We assessed 176 individuals [young adults (n = 22), cognitively unimpaired elderly (n = 89), and cognitively impaired (n = 65)] who underwent amyloid-β PET with 18F-AZD4694, lumbar puncture, structural MRI, and genotyping for APOEε4. 18F-AZD4694 values were normalized using the cerebellar grey matter as a reference region. We compared five methods for deriving a quantitative threshold for 18F-AZD4694 PET positivity: comparison with young controls SUVRs values, Receiver Operating Characteristic (ROC) curves based on clinical classification of CU elderly vs AD dementia, ROC curves based on visual Aβ+/Aβ- classification, Gaussian Mixture Modeling and comparison with cerebrospinal fluid measures of amyloid-β, specifically the Aβ42/Aβ40 ratio. Results: We observed good convergence between four methods ROC curves based on visual classification (optimal cut point: 1.55 SUVR), ROC curves based on clinical classification (optimal cut point: 1.56 SUVR) Gaussian Mixture Modeling (optimal cut point: 1.55 SUVR) and comparison with CSF measures of amyloid-β (optimal cut point: 1.51 SUVR). Means and 2 standard deviations from young controls resulted in a lower threshold (1.33 SUVR) that did not agree with the other methods and labeled the majority of elderly individuals as Aβ+. Conclusion: Good convergence was obtained between a number of methods for determining an optimal cut-off for 18F-AZD4694 PET positivity. Despite conceptual and analytical idiosyncrasies linked with dichotomization of continuous variables, an 18F-AZD4694 threshold of 1.55 SUVR had reliable discriminative accuracy. While clinical use of amyloid-PET currently is made by visual inspection of scans, quantitative thresholds may be helpful to arbitrate disagreement among raters or in borderline cases.
| Type: | Article | 
|---|---|
| Title: | Determining Amyloid-β positivity using [18F]AZD4694 PET imaging | 
| Location: | United States | 
| Open access status: | An open access version is available from UCL Discovery | 
| DOI: | 10.2967/jnumed.120.245209 | 
| Publisher version: | https://doi.org/10.2967/jnumed.120.245209 | 
| Language: | English | 
| Additional information: | Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/ | 
| Keywords: | Alzheimer’s disease, Amyloid-β, Positron Emission Tomography, 18F-AZD4694 | 
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases  | 
        
| URI: | https://discovery.ucl.ac.uk/id/eprint/10107571 | 
Archive Staff Only
![]()  | 
        View Item | 
                      
